11 insiders reported 38 Form 4 transactions for Definium Therapeutics, Inc. (DFTX) over the past 18 months (most recent 2026-09-18). Recent activity: Vallone Carol A (Director) Buy 1,086 shares, Krebs Andreas (Director) Buy 1,629 shares, Sullivan Mark (Chief Legal Officer) Buy 125,000 shares, Roberts Brandi (Chief Financial Officer) Buy 125,000 shares, Wiley Matthew T. (Chief Commercial Officer) Buy 125,000 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Vallone Carol A | Director | Buy | 1,086 | $38,575 |
| 2026-09-18 | Krebs Andreas | Director | Buy | 1,629 | $57,862 |
| 2026-09-14 | Sullivan Mark | Chief Legal Officer | Buy | 125,000 | $0 |
| 2026-09-14 | Roberts Brandi | Chief Financial Officer | Buy | 125,000 | $0 |
| 2026-09-14 | Wiley Matthew T. | Chief Commercial Officer | Buy | 125,000 | $0 |
| 2026-09-14 | Barrow Robert | Chief Executive Officer | Buy | 750,000 | $0 |
| 2026-09-14 | Karlin Daniel | Chief Medical Officer | Buy | 200,000 | $0 |
| 2026-09-04 | Barrow Robert | Chief Executive Officer | Buy | 40,000 | $0 |
| 2026-09-04 | Barrow Robert | Chief Executive Officer | Sell | 19,023 | $721,733 |
| 2026-08-12 | Barrow Robert | Chief Executive Officer | Buy | 375,000 | $0 |
| 2026-08-12 | Roberts Brandi | Chief Financial Officer | Buy | 62,500 | $0 |
| 2026-08-12 | Wiley Matthew T. | Chief Commercial Officer | Buy | 62,500 | $0 |
| 2026-08-12 | Sullivan Mark | Chief Legal Officer | Buy | 62,500 | $0 |
| 2026-08-12 | Karlin Daniel | Chief Medical Officer | Buy | 100,000 | $0 |
| 2026-06-26 | Barrow Robert | Chief Executive Officer | Sell | 29,208 | $1.3M |
| 2026-06-26 | Sullivan Mark | Chief Legal Officer | Sell | 13,008 | $585,750 |
| 2026-06-26 | Roberts Brandi | Chief Financial Officer | Sell | 3,013 | $135,675 |
| 2026-06-26 | Karlin Daniel | Chief Medical Officer | Sell | 10,035 | $451,876 |
| 2026-06-26 | Wiley Matthew T. | Chief Commercial Officer | Sell | 2,867 | $129,101 |
| 2026-06-22 | Sullivan Mark | Chief Legal Officer | Buy | 62,500 | $0 |
| 2026-06-22 | Wiley Matthew T. | Chief Commercial Officer | Buy | 62,500 | $0 |
| 2026-06-22 | Barrow Robert | Chief Executive Officer | Buy | 375,000 | $0 |
| 2026-06-22 | Roberts Brandi | Chief Financial Officer | Buy | 62,500 | $0 |
| 2026-06-22 | Karlin Daniel | Chief Medical Officer | Buy | 100,000 | $0 |
| 2026-06-15 | GRYSKA DAVID W | Director | Buy | 4,666 | $0 |
Source: SEC Form 4 filings · as of 2026-09-18